医学
前列腺癌
临床终点
内科学
肿瘤科
前瞻性队列研究
临床研究阶段
临床试验
癌症
作者
Kato Rans,Steven Joniau,Charlien Berghen,Karolien Goffin,Herlinde Dumez,Karin Haustermans,Gert De Meerleer
标识
DOI:10.1016/j.euo.2024.04.003
摘要
Next-line systemic treatment (NEST) is the standard of care for patients presenting with progressive metastatic castration-resistant prostate cancer (mCRPC). Progression-directed therapy (PDT), defined as a lesion-directed approach in patients with a limited number of progressive and/or new lesions, could postpone the need for NEST in these patients with so-called oligoprogressive mCRPC. Our aim was to investigate the feasibility of postponing NEST initiation in oligoprogressive mCRPC by using PDT.
科研通智能强力驱动
Strongly Powered by AbleSci AI